Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Authors

  • Palanisamy Sivanandy International Medical University, Kuala Lumpur, Malaysia
  • Suresh Shanmugam International Medical University, Kuala Lumpur, Malaysia
  • Rui Ying Lau International Medical University, Kuala Lumpur, Malaysia
  • Jonathan Yvong Syen Chin International Medical University, Kuala Lumpur, Malaysia
  • Xiao Xiang Lee International Medical University, Kuala Lumpur, Malaysia
  • Yun Yun Lau International Medical University, Kuala Lumpur, Malaysia
  • Wai Ching Lee International Medical University, Kuala Lumpur, Malaysia
  • Iqbal Danial Said International Medical University, Kuala Lumpur, Malaysia
  • Jing Ying Lee   International Medical University, Kuala Lumpur, Malaysia
  • Karthikayini Krishnasamy University of Malaya Medical Centre, Kuala Lumpur, Malaysia

DOI:

https://doi.org/10.29169/1927-5951.2020.10.01.8

Keywords:

Metastasis, olaparib, patient, talazoparib, therapy.

Abstract

Breast cancer affect almost 1 in 8 women and it is highest in developed and developing countries. There are many drugs exist for the treatment of breast cancer, but still the incidence of mortality and morbidity are high among all cancer types in most countries. Even though the conventional therapies play a major role in the management of breast cancer, its complications are obvious and unavoidable. The newer targeted drug therapy came in place to reduce complications in some extent, but not fully. Hence, a review was aimed to analyse the efficacy and safety of newer anticancer drugs that approved for the treatment of breast cancer by US-FDA from 2017 to 2019. The Olaparib, Talazoparib, and Ribociclib are the newly approved drugs for the treatment of breast cancer during this review period. Among these new drugs, Olaparib and Talazoparib alone or in combination with other anticancer drugs considered as safe and efficacious. Patients with Olaparib or Talazoparib as monotherapy have median progression-free survival of 2.8 to 8.6 months longer and has 42-46% lower risk of death (P<0.001). A combination of conventional therapies and non-pharmacological approach are warranted for the best benefit of cancer patients and to improve their quality of life.

References

Breast Cancer. Breast Cancer Symptoms. MedlinePlus. Available online: https://medlineplus.gov/breastcancer.html (accessed June 16, 2019).

Ferri FF. Ferri’s Clinical Advisor 2019. 1st ed. Elsevier Health Sciences 2019.

Hartmann LC, Sellers TA, Frost MH, Lingle WL, Dengnim AC, et al. Benign breast disease and the risk of breast cancer. Obstet Gynecol 2016; 71(8): 472-473. https://doi.org/10.1097/01.ogx.0000489578.68399.d7

Malaysia Population Cancer Fact Sheet. The Global Cancer Observatory 2018. Available online: http://gco.iarc.fr/today/ data/factsheets/populations/458-malaysia-fact-sheets.pdf (accessed May 16, 2019).

Freddie B, Jacques F, Isabelle S, Rebecca LS, Lindsey AT, Ahmedin J. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424. https://doi.org/10.3322/caac.21492

Sat Dharam Kaur ND. Global breast cancer incidence 2018. Available online: http://mammalive.net/research/globalbreast- cancer-incidence-2018/ (accessed June 7, 2019).

Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast cancer (Auckl) 2015; 9: BCBCR-S29420. https://doi.org/10.4137/BCBCR.S29420

Aydiner A, Igci A, Soran A. Breast cancer: a guide to clinical practice. Springer. 2018. https://doi.org/10.1007/978-3-319-96947-3

Breast cancer information and support. Available online: https://www.breastcancer.org/ (accessed on May 13, 2019).

Belinda Y, Nicholas CT, Alison J. An update on the medical management of breast cancer. BMJ 2014; 348 :g3608. https://doi.org/10.1136/bmj.g3608

Breast cancer in females. Available online: https://www.clinicalkey.com/#!/content/clinical_overview/67- s2.0-866e25c5-15bf-4016-9ae0-fccae1a3e9e5 (accessed June 16, 2019).

Lynn CH, Thomas AS, Marlene HF, Wilma LL, Amy CD, Karthik G, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005; 353(3): 229-237. https://doi.org/10.1056/NEJMoa044383

Melissa CS, Jerry RB. Breast cancer causes, symptoms, types, treatment & stages. Available online: https://www.emedicinehealth.com/breast_cancer/article_em. htm#what_are_breast_cancer_causes_and_risk_factors (accessed June 17, 2019).

King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302(5645): 643-646. https://doi.org/10.1126/science.1088759

Antoniou A, Pharoah, PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72(5): 1117- 1130. https://doi.org/10.1086/375033

Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62(3): 676-689. PMID: 9497246. https://doi.org/10.1086/301749

Hsieh CC, Trichopoulos D, Katsouyanni K, Yuasa S. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case‐control study. Int J Cancer 1990; 46(5): 796-800. PMID: 2228308. https://doi.org/10.1002/ijc.2910460508

Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the nurses' health study. Am J Epidemiol 1994; 139(8): 819-835. PMID: 8178795. https://doi.org/10.1093/oxfordjournals.aje.a117079

Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V, et al. Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev 2009; 18(1): 169- 176. https://doi.org/10.1158/1055-9965.EPI-08-0808

Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res 2010; 1(2): 109-26. PMID: 22247839.

Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, et al. Implementation of the women's health initiative study design. Ann Epidemiol 2003; 13(9): S5-S17. https://doi.org/10.1016/S1047-2797(03)00043-7

Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the nurses' health study. Am J Epidemiol 2000; 152(10): 950- 964. https://doi.org/10.1093/aje/152.10.950

Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol 2014; 5(3): 283. https://doi.org/10.5306/wjco.v5.i3.283

Lahmann PH, Hoffmann K, Allen N, Van-Gils CH, Khaw KT, Tehard B, et al. Body size and breast cancer risk: findings from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 2004; 111(5): 762-771. https://doi.org/10.1002/ijc.20315

Chlebowski RT. Nutrition and physical activity influence on breast cancer incidence and outcome. Breast 2013; 22(2): S30–S37. https://doi.org/10.1016/j.breast.2013.07.006

Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA 2011; 306(17): 1884- 1890. https://doi.org/10.1001/jama.2011.1590

Ballard T, Lagorio S, De Angelis G, Verdecchia A. Cancer incidence and mortality among flight personnel: a metaanalysis. Aviat Space Environ Med 2000; 71(3): 216-24. PMID: 10716165.

Pukkala E, Kesminiene A, Poliakov S, Ryzho A, Drozdovitch V, Kovgan L, et al. Breast cancer in Belarus and Ukraine after the Chernobyl accident. Int J Cancer 2006; 119(3): 651- 658. https://doi.org/10.1002/ijc.21885

Germain D. Estrogen carcinogenesis in breast cancer. Endocrinol Metab Clin North Am 2011; 40(3): 473-84. https://doi.org/10.1016/j.ecl.2011.05.009

Winchester DJ, Winchester DP, Hudis CA, Norton L. Breast Cancer, 2nd ed. BC Decker: PMPH-USA 2006.

Wang C, Bai F, Zhang LH, Scott A, Li E, Pei XH. Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression. Breast Cancer Res 2018; 20(1): 74. https://doi.org/10.1186/s13058-018-0996-9

Bowcock AM. Breast cancer: molecular genetics, pathogenesis, and therapeutics. Springer Science & Business Media 1999.

Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 2006; 102(1-5): 89-96. https://doi.org/10.1016/j.jsbmb.2006.09.004

Yue W, Wang JP, Li Y, Fan P, Liu G, Zhang N, et al. Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms. Int J Cancer 2010; 127(8): 1748-1757. https://doi.org/10.1002/ijc.25207

McPhee SJ, Hammer G, Kwok Y. Pathophysiology of disease. 8th ed. McGraw-Hill Education LLC: New York USA 2019.

Jin W, Wu L, Liang K, Liu B, Lu Y, Fan Z. Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer 2003; 89(1): 185. https://doi.org/10.1038/sj.bjc.6601048

Dickson RB, Stancel GM. Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr 2000; 27: 135-145. PMID: 10963625. https://doi.org/10.1093/oxfordjournals.jncimonographs.a0242 37

Pietras RJ, Marquez-Garban DC. Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res 2007; 13(16): 4672–4676. https://doi.org/10.1158/1078-0432.CCR-07-1373

Taib NA, Yip CH, Low WY. Recognising symptoms of breast cancer as a reason for delayed presentation in Asian womenthe psycho-socio-cultural model for breast symptom appraisal: opportunities for intervention. Asian Pac J Cancer Prev 2011; 12(6): 1601-8. PMID: 22126506.

Singh D, Miettinen J, Duffy S, Malila N, Pitkaniemi J, Anttila A. Association of symptoms and interval breast cancers in the mammography-screening programme: population-based matched cohort study. Br J Cancer 2018; 119(11): 1428. https://doi.org/10.1038/s41416-018-0308-2

Papadakis MA, McPhee SJ, Bernstein J. Quick Medical Diagnosis and Treatment. McGraw-Hill: New York USA 2019.

Breast cancer. Centers for Disease Control and Prevention. Available online: http://www.cdc.gov/obesity/downloads/ PA_2011_WEB.pdf (accessed June 20, 2019).

Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast. 5th ed. Wolters Kluwer Health: Philadelphia USA 2014.

Usatine RP, Smith MA, Chumley HS, Mayeaux EJ. The Color Atlas of Family Medicine. 2nd ed. McGraw-Hill: New York USA 2013.

Wahl RL, Imaging. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. Abeloff’s Clinical Oncology. 4th ed. Churchill Livingstone 2014; 18: pp. 242- 246.

Hayes DF, Lippman ME. Breast Cancer. In: Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison's Principles of Internal Medicine. 20th ed. McGraw- Hill: New York 2018.

Fernando J, Jones R. The principles of cancer treatment by chemotherapy. Surg Oxf 2015; 33(3): 131-135. https://doi.org/10.1016/j.mpsur.2015.01.005

American Cancer Society. Information and resources about for cancer: breast, colon, lung, prostate, skin. Available online: https://www.cancer.org/ (accessed June 13, 2019).

MacNeill F, Karakatsanis A. Over surgery in breast cancer. Breast 2017; 31: 284-289. https://doi.org/10.1016/j.breast.2016.10.023

National Breast Cancer Foundation. Available online: https://www.nationalbreastcancer.org/ (accessed May 13, 2019).

Scholar E. Antimetabolites. xPharm: The comprehensive pharmacology reference 2007: 1-4. https://doi.org/10.1016/j.biopha.2018.02.108

Wu Y, Zhang D, Wu B, Quan Y, Liu D, Li Y, et al. Synergistic activity of an antimetabolite drug and tyrosine kinase inhibitors against breast cancer cells. Chem Pharm Bull 2017; 65(8): 768-775. https://doi.org/10.1248/cpb.c17-00261

Methotrexate. BC cancer agency cancer drug manual

[Monograph on the internet]. BC Cancer Agency Cancer Drug Manual; 2017

[cited 2019 May 13]: 1-16. Available online: http://www.bccancer.bc.ca/drug-databasesite/ Drug%20Index/Methotrexate_monograph.pdf

Abotaleb M, Kubatka P, Caprnda M, Varghese E, Zolakova B, Zubor P, et al. Chemotherapeutic agents for the treatment of metastatic breast cancer: an update. Biomed Pharmacother 2018; 101: 458-477. https://doi.org/10.1016/j.biopha.2018.02.108

Inoue K, Yuasa H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab Pharmacokinet 2014; 29(1): 12-19. PMID: 24284432. https://doi.org/10.2133/dmpk.DMPK-13-RV-119

Avendano C, Menendez JC. Antimetabolites. Med Chem Anticancer Drugs 2008; 9: 52. https://doi.org/10.1016/B978-0-444-52824-7.00002-0

Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev 2011; 31(3): 443-481. https://doi.org/10.1002/med.20242

Hevener K, Verstak TA, Lutat KE, Riggsbee DL, Mooney JW. Recent developments in topoisomerase-targeted cancer chemotherapy. Acta Pharm Sin B 2018; 8(6): 844-861. https://doi.org/10.1016/j.apsb.2018.07.008

Bush NG, Evans-Roberts K, Maxwell A. DNA topoisomerases. EcoSal Plus 2015; 6(2): 67-81. https://doi.org/10.1128/ecosalplus.ESP-0010-2014

Kathiravan MK, Kale AN, Nilewar S. Discovery and development of topoisomerase inhibitors as anticancer agents. Mini Rev Med Chem 2016; 16(15): 1219-1229. PMID: 27549098. https://doi.org/10.2174/1389557516666160822110819

Damiani RM, Moura DJ, Viau CM, Brito V, Moras AM, Henriques JAP, et al. Influence of PARP-1 inhibition in the cardiotoxicity of the topoisomerase 2 inhibitors doxorubicin and mitoxantrone. Toxicol In vitro 2018; 52: 203-213. https://doi.org/10.1016/j.tiv.2018.06.013

Scholar E. Alkylating agents. xPharm: The comprehensive pharmacology reference 2007: 1-4. https://doi.org/10.1016/B978-008055232-3.61034-7

Charlene AM. Carcinogenic alkylating agents. In: La DK, Upton PB, Swenberg JA. Comprehensive Toxicology. 2nd ed. Science Direct 2010; pp. 63-83. https://doi.org/10.1016/B978-0-08-046884-6.01405-6

Peter NB, Morris JB, Pankaj S. Neoplastic disease and immunosuppression. In: Wasan H. Clinical Pharmacology. 11th ed. Churchill Livingstone 2012; pp. 509-525. https://doi.org/10.1016/B978-0-7020-4084-9.00070-7

Frank JD, Barton SJ, Angelo JM. Antineoplastic Drugs. In: Kwok KK, Vincent EC, Gibson JN. Pharmacology and therapeutics for dentistry. 7th ed. Mosby 2017; pp. 530-562. https://doi.org/10.1016/B978-0-323-39307-2.00036-9

Egger SJ, Willson ML, Morgan J, Walker HS, Carrick S, Ghersi D, et al. Platinum‐containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2017; 6: CD003374. https://doi.org/10.1002/14651858.CD003374.pub4

Zhao H, Yang Q, Hu Y, Zhang J. Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple negative breast cancer cells. Oncol Rep 2018; 40(6): 3223-3234. https://doi.org/10.3892/or.2018.6716

O'sullivan CC, Loprinzi CL, Haddad TC. Updates in the evaluation and management of breast cancer. Mayo Clin Proc 2018; 93(6): 794-807. https://doi.org/10.1016/j.mayocp.2018.03.025

Becourt S, Espie M. Hormonal treatment of breast cancer. In: Encyclopedia of Endocrine Diseases. 2019; pp. 646-655. https://doi.org/10.1016/B978-0-12-801238-3.64351-9

Hormone therapy for breast cancer. Available online: https://www.cancer.gov/types/breast/breast-hormonetherapy- fact-sheet (accessed July 20, 2019).

Hormone therapy for breast cancer. American Cancer Society. Available online: https://www.cancer.org/cancer/ breast-cancer/treatment/hormone-therapy-for-breastcancer. html (accessed July 20, 2019).

Draganescu M, Carmocan C. Hormone therapy in breast cancer. Chirurgia (Bucur) 2017; 112(4): 413-417. https://doi.org/10.21614/chirurgia.112.4.413

Godone RLN, Leitao GM, Araujo NB, Castelletti CHM, Lima- Filho JL, Martins DBG. Clinical and molecular aspects of breast cancer: Targets and therapies. Biomed Pharmacother 2018; 106: 14-34. https://doi.org/10.1016/j.biopha.2018.06.066

Ju J, Zhu AJ, Yuan P. Progress in targeted therapy for breast cancer. Chronic Dis Transl Med 2018; 4(3): 164-175. https://doi.org/10.1016/j.cdtm.2018.04.002

FDA approves olaparib for germline BRCA-mutated metastatic breast cancer. Available online: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDru gs/ucm592357.htm (accessed July 21, 2019).

Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A. PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Prz Menopauzalny 2016; 15(4): 215-219. https://doi.org/10.5114/pm.2016.65667

Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Eng J Med 2017; 377(6): 523- 533. https://doi.org/10.1056/NEJMoa1706450

US Food and Drug Administration. FDA approves talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancer. Available online: https://www.fda.gov/Drugs/ InformationOnDrugs/ApprovedDrugs/ucm623540.htm (accessed July 25, 2019].

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Eng J Med 2018: 379(8): 753-763. https://doi.org/10.1056/NEJMoa1802905

Talzenna (talazoparib). Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/ 211651s000lbl.pdf (accessed July 20, 2019).

Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al. A phase II study of Talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO). Clin Cancer Res 2019; 25(9): 2717-2724. https://doi.org/10.1158/1078-0432.CCR-18-1891

Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clin Cancer Res 2017; 23(13): 3251-3262. https://doi.org/10.1158/1078-0432.CCR-16-3157

O'Shaughnessy J, Petrakova K, Sonke GS, Conte P, Arteaga CL, Cameron DA, et al. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat 2018; 168: 127-134. https://doi.org/10.1007/s10549-017-4518-8

Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of Ribociclib and Fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 2018; 36(24): 2465-2472. https://doi.org/10.1200/JCO.2018.78.9909

Breast cancer care and prevention: non-pharmacological intervention. University of Wisconsin integrative medicine. Available online: https://www.fammed.wisc.edu/files/webfmuploads/ documents/outreach/im/module_breast_ca_clinician. pdf (accessed July 20, 2019).

Pujol LA, Monti DA. Managing cancer pain with nonpharmacologic and complementary therapies. J Am Osteopath Assoc 2007; 107: ES15-ES21. PMID: 18165373.

Daniels S. Cognitive behavior therapy for patients with cancer. J Adv Pract Oncol 2015; 6: 54-6. PMID: 26413374. https://doi.org/10.6004/jadpro.2015.6.1.5

Downloads

Published

2020-01-05

How to Cite

Palanisamy Sivanandy, Suresh Shanmugam, Rui Ying Lau, Jonathan Yvong Syen Chin, Xiao Xiang Lee, Yun Yun Lau, Wai Ching Lee, Iqbal Danial Said, JingYingLee , & Karthikayini Krishnasamy. (2020). Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer. Journal of Pharmacy and Nutrition Sciences, 10(1), 46–59. https://doi.org/10.29169/1927-5951.2020.10.01.8

Issue

Section

Articles

Similar Articles

You may also start an advanced similarity search for this article.